Saravanabavan Sujen, McKernan Patrick, Cameron Scott, Kwan Natasha, Kang Kristopher T, Roberts Ashley, Carr Roxane, Mak Raymond, Elwood Chelsea, Paquette Vanessa, Stimpson Rochelle, Abrahams Bethina, Chan Edmond S, Slayter Kathryn, Rahier Alicia, Sainchuk Irina, Olsen Sharla, Kucey Melissa, Shamseddine Jinan, Babiker Zahir Osman Eltahir, Wong Tiffany
BC Children's Hospital, 4480 Oak Street, Room 1C31B, Oak Street Entrance, 1982 Building, Djavid Mowafaghian Wing, Vancouver, BC, V6H 3V4, Canada.
Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
Allergy Asthma Clin Immunol. 2024 Dec 23;20(1):73. doi: 10.1186/s13223-024-00942-3.
Many clinicians feel uncomfortable with de-labelling penicillin allergies despite ample safety data. Point of care tools effectively support providers with de-labelling. This study's objective was to increase the number of providers intending to pursue a penicillin oral challenge by 15% by February 2023.
A validated de-labelling algorithm was translated into an electronic point of care tool and disseminated to eight healthcare institutions. Applying the Model for Improvement Framework, three PDSA cycles were conducted, where collected data and completed surveys were analysed to implement changes. Number of providers intending to pursue an oral challenge, tool usage as well as number of clinicians who felt satisfied with the tool and felt confident in its ability to risk-stratify patients was collected.
50.4% of providers intended to give an oral challenge of penicillin with version 1, which improved to 65.5% with version 2, representing a 15.1% increase. With version 1 of the tool, there was an average of 61.3 counts of tool usage per month. 73.1% of providers felt satisfied with the tool and 76.9% felt confident in its ability to risk-stratify patients. With version 2 of the tool, after implementing changes through three PDSA cycles, monthly usage counts increased to an average of 98.6. Furthermore, 100.0% of providers felt satisfied with the tool and 98.1% felt confident with the tool's ability to risk-stratify patients.
Our quality improvement approach demonstrated improvement in the percentage of providers that intended to pursue an oral challenge and felt satisfied and confident in the risk-stratification capabilities of penicillin allergy de-labelling tool. Electronic tools should be further incorporated into institutional penicillin de-labelling protocols.
尽管有充分的安全数据,但许多临床医生对消除青霉素过敏标签仍感到不自在。即时护理工具能有效地支持医疗服务提供者进行消除标签操作。本研究的目标是到2023年2月,使打算进行青霉素口服激发试验的医疗服务提供者数量增加15%。
将经过验证的消除标签算法转化为电子即时护理工具,并分发给八家医疗机构。应用改进模型框架进行了三个计划-执行-检查-处理(PDSA)循环,对收集的数据和完成的调查进行分析以实施改进。收集了打算进行口服激发试验的医疗服务提供者数量、工具使用情况,以及对该工具感到满意并对其对患者进行风险分层的能力有信心的临床医生数量。
使用版本1时,50.4%的医疗服务提供者打算进行青霉素口服激发试验,使用版本2时这一比例提高到65.5%,增长了15.1%。使用版本1的工具时,每月平均使用次数为61.3次。73.1%的医疗服务提供者对该工具感到满意,76.9%的人对其对患者进行风险分层的能力有信心。使用版本2的工具时,通过三个PDSA循环实施改进后,每月使用次数平均增加到98.6次。此外,100.0%的医疗服务提供者对该工具感到满意,98.1%的人对该工具对患者进行风险分层的能力有信心。
我们的质量改进方法表明,打算进行口服激发试验的医疗服务提供者的比例有所提高,并且对青霉素过敏消除标签工具的风险分层能力感到满意和有信心。应将电子工具进一步纳入机构青霉素消除标签方案中。